Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy
First Claim
1. A method of treating with oxybutynin a human subject having overactive bladder, while minimizing an anticholinergic or antimuscarinic adverse drug experience associated with said oxybutynin treatment therapy comprising the step of:
- administering as a transdermal patch, a composition comprising oxybutynin to said subject for a duration of from about 24 to about 96 hours to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5;
1 to about 5;
1, wherein the transdermal patch optionally includes a permeation enhancer.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder.
47 Citations
24 Claims
-
1. A method of treating with oxybutynin a human subject having overactive bladder, while minimizing an anticholinergic or antimuscarinic adverse drug experience associated with said oxybutynin treatment therapy comprising the step of:
administering as a transdermal patch, a composition comprising oxybutynin to said subject for a duration of from about 24 to about 96 hours to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5;
1 to about 5;
1, wherein the transdermal patch optionally includes a permeation enhancer.- View Dependent Claims (3, 4, 5, 6, 7, 9, 10, 12)
-
2. A method of treating with oxybutynin a human subject having overactive bladder, while minimizing an anticholinergic or antimuscarinic adverse drug experience associated with said oxybutynin treatment therapy comprising the step of:
administering as a transdermal patch, a composition comprising oxybutynin to said subject for a duration of up to 96 hours to provide a plasma area under the curve (AUC) ratio of oxybutynin to an oxybutynin metabolite of from about 0.5;
1 to about 5;
1, wherein the transdermal patch optionally includes a permeation enhancer.
-
8. The method of claim 8, wherein the oxybutynin is R-oxybutynin.
-
13. An article of manufacture for transdermal application comprising:
a transdermal patch including a composition of oxybutynin and optionally a permeation enhancer for administration to a human subject, wherein the patch provides, upon administration to said subject for a duration of from about 24 to about 96 hours, a plasma AUC ratio of oxybutynin to an oxybutynin metabolite from about 0.5;
1 to about 5;
1, and wherein said patch minimizes an anticholinergic or antimuscarinic adverse drug experience associated with the administration of oxybutynin.- View Dependent Claims (15, 16, 17, 18, 19, 20, 21, 22, 23, 24)
-
14. An article of manufacture for transdermal application comprising:
a transdermal patch including a composition of oxybutynin and optionally a permeation enhancer for administration to a human subject, wherein the patch provides, upon administration to said subject for a duration of up to 96 hours, a plasma AUC ratio of oxybutynin to an oxybutynin metabolite from about 0.5;
1 to about 5;
1, and wherein said patch minimizes an anticholinergic or antimuscarinic adverse drug experience associated with the administration of oxybutynin.
Specification